Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Coordinating Biologic Therapy, Monitoring, and Vaccinations in Adolescents Transitioning to Adult Care
Description
The talk focused on how dermatology and primary care can better coordinate care for adolescents on biologic therapy as they transition to adult care. The speaker emphasized that transition planning should begin early, with shared accountability among pediatric and adult clinicians, parents, and patients, and should account for the psychosocial burdens of chronic illness, school, work, stigma, and family conflict. Shared decision-making was presented as a practical framework, but one that must recognize real-world constraints such as insurance, cost, access, and the possibility that patients may seek care elsewhere if they feel unheard. The speaker highlighted the value of structured documentation, standardized monitoring plans, patient handouts, and shared decision aids to make visits predictable, efficient, and less overwhelming, especially for teens who may resist lengthy appointments. Two cases illustrated severe hidradenitis suppurativa and eczema, showing the importance of escalating therapy appropriately, anticipating future transition needs, and coordinating follow-up and lab monitoring. Vaccination counseling was another major theme: inactivated vaccines are safe for patients on biologics, live vaccines require more caution and data, and clinicians should proactively discuss age-appropriate immunizations, especially during transitions such as college entry or moving to a new provider. Overall, the message was to use communication, structure, and collaboration to improve outcomes and reduce treatment burden.
View moreConclusions
- Effective care for adolescents on biologics requires early, structured transition planning that connects pediatric and adult teams and does not rely on a sudden transfer of responsibility.
- Shared decision-making works best when patients, parents, and clinicians are all engaged, with clinicians actively advocating rather than remaining neutral about escalation of care.
- Chronic dermatologic disease can disrupt education, relationships, mental health, and the path to adulthood, so treatment decisions should account for psychosocial as well as physical burden.
- Using standardized tools, written handouts, and predictable follow-up can make monitoring biologics more efficient, less overwhelming, and more likely to keep adolescents engaged in care.
- Complex patients with hidradenitis suppurativa or severe eczema often need timely biologic therapy and careful monitoring, but treatment plans must also anticipate cost, insurance, and access barriers.
- A clinician saying no is not the end of care, because patients may seek alternatives or delay treatment unless the care team helps navigate barriers and options.
- Vaccination planning should be integrated into biologic management, with age-appropriate immunizations addressed before and during therapy through coordination with primary care.
- Inactivated vaccines are generally safe during biologic treatment, while live vaccines require more caution and may depend on the specific drug and guideline.
- Patients on biologics still need comprehensive primary care, including routine preventive screening, and dermatology should reinforce rather than replace that broader medical care.
- Overall, the presentation argues that structured communication and collaboration across specialties improve trust, adherence, and long-term outcomes for adolescents receiving immunomodulatory therapy.
- Hightower and Lipsitz; Fair Housing for Our Future, Laws & Litigation Conference 2022.
- White and Cooley, 2018 Oct 22.
- Lee et al, Dermatological Reviews 2022.
- Toledo et al, JAAD Int 2022.
- Kavanaugh, Current Opinion in Rheumatology, 2009.
- Cush, Drug Safety Quarterly, 2013.